COMMUNIQUÉS West-GlobeNewswire

FIT Biotech Oy: EHVA starts recruiting participants to clinical trial testing FIT Biotech's vaccine
27/11/2018
FIT Biotech Oy Company release 27.11.2018 at 03:00 PM EET EHVA starts recruiting participants to clinical trial testing FIT Biotech's vaccine European EHVA-vaccine alliance (European HIV Vaccine Alliance, EHVA) starts [...]
BioSig Technologies Signs Agreement with Texas Cardiac Arrhythmia Institute for First–in-Human Studies
27/11/2018
Santa Monica, CA, Nov. 27, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet [...]
Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test
27/11/2018
TREETOP Study will Explore Enhancements to Sera’s Validated PreTRM ® Test SALT LAKE CITY, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company, announced today that it has completed [...]
PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
27/11/2018
MALVERN, Pa. and SAN DIEGO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel [...]
electroCore Expands Manufacturing Capabilities for gammaCore™
27/11/2018
BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development [...]
Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
27/11/2018
BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study
27/11/2018
SAINT LAURENT, Quebec, Nov. 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a study of Montelukast [...]
Evelo Enters into Clinical Trial Collaboration Agreement with Merck
27/11/2018
-- Initiation of Phase 1/2 Combination Clinical Trial with Evelo’s Monoclonal Microbial, EDP1503, and KEYTRUDA® (pembrolizumab) Across Various Indications Expected in First Half of 2019 -- CAMBRIDGE, Mass., Nov. 27, [...]
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
27/11/2018
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today [...]
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
27/11/2018
REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing [...]
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
27/11/2018
Appointment Strengthens Development Leadership to Support Growing Pipeline of Innovative ADCs CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage [...]
Pediapharm Announces Q2 Results – Record Adjusted EBITDA, Record Revenue and 13th Consecutive Year-Over-Year Quarterly Revenue Growth
27/11/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Nov. 27, [...]
Pediapharm annonce les résultats de son deuxième trimestre – BAIIA ajusté record, ventes records et un 13e trimestre consécutif de croissance d’un exercice à l’autre
27/11/2018
CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS. MONTRÉAL, 27 [...]
Zogenix to Participate in the Global Mizuho Investor Conference 2018
27/11/2018
EMERYVILLE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]
Biotricity Builds Capacity with University of Calgary and Receives Ethics Approvals for Research
27/11/2018
New R&D Program Establishes Ambulatory “Wellness” & Non-Invasive Labor Monitoring with Heart Rate Variability REDWOOD CITY, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB : BTCY ), a medical [...]
Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer
27/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced that it has named [...]
Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases
27/11/2018
TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is [...]
HealthLynked Announces the Release of its New Patient and Provider Websites and Improved Provider Profiles
27/11/2018
NAPLES, Fla., Nov. 27, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced the company has updated its Provider and Patient websites. The new websites better illustrate the wide range of services [...]
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
27/11/2018
SYDNEY, Australia, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial is being presented at the [...]

Pages